Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 12Burkitt Lymphoma 8Lymphoma, Follicular 7Sarcoma 5Lymphoma, Non-Hodgkin 5Hodgkin Disease 5Neoplasms 4Lymphoma 4Wilms Tumor 3Sarcoma, Ewing 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Lymphoma, B-Cell 3Liposarcoma 3Endometrial Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2Down Syndrome 2Dermatofibrosarcoma 2

Interventions

Nuclear Medicine Department, Hospital 6Magnetic Resonance Spectroscopy 6X-Rays 5Specimen Handling 5Phantoms, Imaging 5Biopsy 5Temozolomide 4Irinotecan 3ulixertinib 2tipifarnib 2selpercatinib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2dinutuximab 2Cyclophosphamide 2trametinib 1tazemetostat 1talazoparib 1saponin QA-21V1 1palbociclib 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1fludarabine phosphate 1fludarabine 1dabrafenib 1Vincristine 1Vemurafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Doxorubicin × 30 days × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡